Sunday, September 29, 2024
HomeTagsPitolisant

pitolisant

Harmony Biosciences Announces Plans To Initiate Phase 3 Clinical Trial For Treatment Of Idiopathic Hypersomnia

Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics